Highly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expression.
Vaccinia viruses defective in the essential gene coding for the enzyme uracil DNA glycosylase (UDG) do not undergo DNA replication and do not express late genes in wild-type cells. A UDG-deficient vaccinia virus vector carrying the tick-borne encephalitis (TBE) virus prM/E gene, termed vD4-prME, was constructed, and its potential as a vaccine vector was evaluated. High-level expression of the prM/E antigens could be demonstrated in infected complementing cells, and moderate levels were found under noncomplementing conditions. The vD4-prME vector was used to vaccinate mice; animals receiving single vaccination doses as low as 10(4) PFU were fully protected against challenge with high doses of virulent TBE virus. Single vaccination doses of 10(3) PFU were sufficient to induce significant neutralizing antibody titers. With the corresponding replicating virus, doses at least 10-fold higher were needed to achieve protection. The data indicate that late gene expression of the vaccine vector is not required for successful vaccination; early vaccinia virus gene expression induces a potent protective immune response. The new vaccinia virus-based defective vectors are therefore promising live vaccines for prophylaxis and cancer immunotherapy.
Holzer
G W
GW
Baxter/Hyland Immuno Division, Biomedical Research Center, A-2304 Orth/Donau, Austria.
Remp
G
G
Antoine
G
G
Pfleiderer
M
M
Enzersberger
O M
OM
Emsenhuber
W
W
Hämmerle
T
T
Gruber
F
F
Urban
C
C
Falkner
F G
FG
Dorner
F
F
D000818:Animals; D004261:DNA Replication; D003673:Defective Viruses / Q000235:genetics*; D004669:Encephalitis Viruses, Tick-Borne / Q000276:immunology*; D005822:Genetic Vectors; D051379:Mice; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000276:immunology*; D014616:Vaccinia virus / Q000235:genetics*; D014765:Viral Vaccines / Q000276:immunology*; D014779:Virus Replication
D014614:Vaccines, Synthetic; D014765:Viral Vaccines